氨吡酮(Amrinone)是七十年代美国Sterling制药公司研究开发的一类既非洋地黄强力甙,又非儿茶酚胺类的新型正性肌力药物。据文献报导对心力衰竭患者的治疗效果显著。氨吡酮于1984年7月由美国FDA批准临床应用。该药主要不良反应为可逆性血小板减少。据国外报导氨吡酮用于治疗心衰病人很少发生心律失常,目前国内尚未见有关临床应用氨吡酮引起室性心律失常的报 Amrinone is a new type of inotropic drug developed and researched by Sterling Pharmaceuticals in the seventies in the United States, which is not digitalis glycosides nor catecholamines. According to the literature on the treatment of patients with heart failure results were significant. Pirathonone was approved by the FDA in July 1984 for clinical use. The drug’s main adverse reaction is reversible thrombocytopenia. According to foreign reports of pyriprenil for the treatment of heart failure rarely arrhythmia, at present there is no clinical application of intravenous arginin induced ventricular arrhythmia reported